SCHEMBL4340216

SCHEMBL4340216

NC(=S)N/N=C/c1ccc(N2CCN(Cc3ccccc3Cl)CC2)c(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.56
ALDH1A1 P00352 4/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
KDM4E B2RXH2 4/20 0.51
PLA2G1B P04054 1/20 0.51
RAB9A P51151 1/20 0.51
ATG4B Q9Y4P1 1/20 0.51
POLB P06746 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
KMT2A Q03164 1/20 0.47
LMNA P02545 2/20 0.46
HTT P42858 2/20 0.46
MAPK1 P28482 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
GAA P10253 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4340219 1.00 MAPT (0.56) MAPTALDH1A1SMN1; SMN2TDP1KDM4E
SCHEMBL4336606 0.92 ALDH1A1 (0.49) MAPTALDH1A1SMN1; SMN2TDP1KDM4E
SCHEMBL4326722 0.92 ALDH1A1 (0.49) MAPTALDH1A1SMN1; SMN2TDP1KDM4E
SCHEMBL4336603 0.92 ALDH1A1 (0.49) MAPTALDH1A1SMN1; SMN2TDP1KDM4E
SCHEMBL4326719 0.92 ALDH1A1 (0.49) MAPTALDH1A1SMN1; SMN2TDP1KDM4E
SCHEMBL4322333 0.91 MAPT (0.47) MAPTALDH1A1SMN1; SMN2TDP1KDM4E
SCHEMBL4322328 0.91 MAPT (0.47) MAPTALDH1A1SMN1; SMN2TDP1KDM4E
SCHEMBL4338744 0.90 ALDH1A1 (0.47) MAPTALDH1A1SMN1; SMN2TDP1KDM4E
SCHEMBL4338739 0.90 ALDH1A1 (0.47) MAPTALDH1A1SMN1; SMN2TDP1KDM4E
SCHEMBL4334389 0.89 MAPT (0.45) MAPTALDH1A1SMN1; SMN2TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAPT 3619/4885ALDH1A1 1459/4885SMN1; SMN2 4740/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAPT 3876/4885ALDH1A1 1173/4885SMN1; SMN2 4815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.